Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 3/2017

01-03-2017 | Editorial

The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis

Authors: Silvia Morbelli, Javier Arbizu, Jan Booij, Ming-Kai Chen, Gael Chetelat, Donna J. Cross, Mehdi Djekidel, Alexander Drzezga, Ozgul Ekmekcioglu, Valentina Garibotto, Swen Hesse, Kazunari Ishii, Lida Jafari Saraf, Adriaan A. Lammertsma, Ian Law, Dana Mathews, Satoshi Minoshima, Karina Mosci, Marco Pagani, Sabina Pappata, Daniel Hillel Silverman, Alberto Signore, Elsmarieke Van De Giessen, Victor Villemagne, Henryk Barthel, on behalf of the European Association of Nuclear Medicine (EANM) and of the Society of Nuclear Medicine and Molecular Imaging (SNMMI)

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2017

Login to get access

Excerpt

[18F]FDG PET is currently the most commonly used functional imaging method for the in vivo investigation of regional brain metabolism in clinical practice. PET/CT scanners are widely available in Europe, in the US, in Australia, and most of the rest of the world [1] and the clinical role of [18F]FDG brain PET can be regarded as established for a number of diagnostic challenges in Neurology and Psychiatry [2]. In particular, [18F]FDG PET plays a major role in the early and differential diagnosis of neurodegenerative dementias and Parkinsonian syndromes by showing disease-specific patterns of hypometabolism [3]. For a substantial period of time, however, the lack of standardisation in reading images and reporting results, as well as the lack of large studies in homogeneous patient cohorts, has delayed a wider routine clinical use of [18F]FDG PET [4]. This is particularly true in the field of inflammation/infection imaging despite initial attempts to standardize this methodology between the European Association of Nuclear Medicine (EANM) and the American Society of Nuclear medicine and Molecular Imaging (SNMMI) [5]. In the last decade, thanks to the synergistic efforts of the neuroimaging and neurological communities across different countries, larger data sets and functional imaging repositories have become available. This allowed for assessing the clinical value of [18F]FDG PET as well as that of other imaging biomarkers in the field of neurodegenerative diseases [68]. The added value of this large multi-center approach has gained attention in the US for PET imaging in other indications as well, for example, through the National Oncologic PET Registry (NOPR) and more recently the Imaging Dementia Evidence for Amyloid Scanning (IDEAS) clinical trials. Similarly, software based semi-quantitative approaches have increasingly been used both in the context of published group analyses as well as in clinical practice, thus testifying that objective measures can be incorporated and added to the traditional analysis approach in nuclear medicine, i.e., visual reading [911]. …
Literature
1.
go back to reference National Research Council (US) and Institute of Medicine (US) Committee on State of the Science of Nuclear Medicine. Advancing Nuclear Medicine Through Innovation, Washington (DC): National Academies Press (US); ISBN-13: 978-0-309-11067-9, ISBN-10: 0-309-11067-X; 2007. National Research Council (US) and Institute of Medicine (US) Committee on State of the Science of Nuclear Medicine. Advancing Nuclear Medicine Through Innovation, Washington (DC): National Academies Press (US); ISBN-13: 978-0-309-11067-9, ISBN-10: 0-309-11067-X; 2007.
2.
go back to reference Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, Någren K, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36:2103–10.CrossRefPubMed Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, Någren K, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36:2103–10.CrossRefPubMed
3.
go back to reference Herholz K. Guidance for reading FDG PET scans in dementia patients. Q J Nucl Med Mol Imaging. 2014;58:332–43.PubMed Herholz K. Guidance for reading FDG PET scans in dementia patients. Q J Nucl Med Mol Imaging. 2014;58:332–43.PubMed
4.
go back to reference Morbelli S, Garibotto V, Van De Giessen E, Arbizu J, Chételat G, Drezgza A, et al. A cochrane review on brain [18F]FDG PET in dementia: limitations and future perspectives. Eur J Nucl Med Mol Imaging. 2015;42:1487–91.CrossRefPubMed Morbelli S, Garibotto V, Van De Giessen E, Arbizu J, Chételat G, Drezgza A, et al. A cochrane review on brain [18F]FDG PET in dementia: limitations and future perspectives. Eur J Nucl Med Mol Imaging. 2015;42:1487–91.CrossRefPubMed
5.
go back to reference Jamar F, Buscombe J, Chiti A, Christian PE, Delbeke D, Donohoe KJ, et al. EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med. 2013;54:647–58.CrossRefPubMed Jamar F, Buscombe J, Chiti A, Christian PE, Delbeke D, Donohoe KJ, et al. EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med. 2013;54:647–58.CrossRefPubMed
6.
go back to reference Hendrix JA, Finger B, Weiner MW, Frisoni GB, Iwatsubo T, Rowe CC, et al. The worldwide Alzheimer’s disease neuroimaging initiative: an update. Alzheimers Dement. 2015;11:850–9.CrossRefPubMed Hendrix JA, Finger B, Weiner MW, Frisoni GB, Iwatsubo T, Rowe CC, et al. The worldwide Alzheimer’s disease neuroimaging initiative: an update. Alzheimers Dement. 2015;11:850–9.CrossRefPubMed
7.
go back to reference Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J, et al. 2014 update of the Alzheimer’s disease neuroimaging initiative: a review of papers published since its inception. Alzheimers Dement. 2015;11:e1–120.CrossRefPubMed Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J, et al. 2014 update of the Alzheimer’s disease neuroimaging initiative: a review of papers published since its inception. Alzheimers Dement. 2015;11:e1–120.CrossRefPubMed
8.
go back to reference Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer’s disease. Int Psychogeriatr. 2009;21:672–87.CrossRefPubMed Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer’s disease. Int Psychogeriatr. 2009;21:672–87.CrossRefPubMed
9.
go back to reference Herholz K, Westwood S, Haense C, Dunn G. Evaluation of a calibrated (18)F-FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. J Nucl Med. 2011;52:1218–26.CrossRefPubMed Herholz K, Westwood S, Haense C, Dunn G. Evaluation of a calibrated (18)F-FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. J Nucl Med. 2011;52:1218–26.CrossRefPubMed
10.
go back to reference Perani D, Della Rosa PA, Cerami C, Gallivanone F, Fallanca F, Vanoli EG, et al. Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. Neuroimage Clin. 2014;6:445–54.CrossRefPubMedPubMedCentral Perani D, Della Rosa PA, Cerami C, Gallivanone F, Fallanca F, Vanoli EG, et al. Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. Neuroimage Clin. 2014;6:445–54.CrossRefPubMedPubMedCentral
11.
go back to reference Morbelli S, Brugnolo A, Bossert I, Buschiazzo A, Frisoni GB, Galluzzi S, et al. Visual versus semi-quantitative analysis of 18F-FDG-PET in amnestic MCI: an European Alzheimer’s Disease Consortium (EADC) project. J Alzheimers Dis. 2015;44:815–26.PubMed Morbelli S, Brugnolo A, Bossert I, Buschiazzo A, Frisoni GB, Galluzzi S, et al. Visual versus semi-quantitative analysis of 18F-FDG-PET in amnestic MCI: an European Alzheimer’s Disease Consortium (EADC) project. J Alzheimers Dis. 2015;44:815–26.PubMed
12.
go back to reference Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15:391–404.CrossRefPubMed Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15:391–404.CrossRefPubMed
13.
go back to reference Vollmer TL, McCarthy M. Autoimmune encephalitis: a more treatable tragedy if diagnosed early. Neurology. 2016;86(18):1655–6.CrossRefPubMed Vollmer TL, McCarthy M. Autoimmune encephalitis: a more treatable tragedy if diagnosed early. Neurology. 2016;86(18):1655–6.CrossRefPubMed
14.
go back to reference Heine J, Prüss H, Bartsch T, Ploner CJ, Paul F, Finke C. Imaging of autoimmune encephalitis - relevance for clinical practice and hippocampal function. Neuroscience. 2015;309:68–83.CrossRefPubMed Heine J, Prüss H, Bartsch T, Ploner CJ, Paul F, Finke C. Imaging of autoimmune encephalitis - relevance for clinical practice and hippocampal function. Neuroscience. 2015;309:68–83.CrossRefPubMed
15.
go back to reference Baumgartner A, Rauer S, Mader I, Meyer PT. Cerebral FDG-PET and MRI findings in autoimmune limbic encephalitis: correlation with autoantibody types. J Neurol. 2013;260:2744–53.CrossRefPubMed Baumgartner A, Rauer S, Mader I, Meyer PT. Cerebral FDG-PET and MRI findings in autoimmune limbic encephalitis: correlation with autoantibody types. J Neurol. 2013;260:2744–53.CrossRefPubMed
16.
go back to reference Morbelli S, Djekidel M, Hesse S, Pagani M, Barthel H, Neuroimaging Committee of the European Association of Nuclear Medicine (EANM); Brain Imaging Council of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Role of (18)F-FDG-PET imaging in the diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15:1009–10.CrossRefPubMed Morbelli S, Djekidel M, Hesse S, Pagani M, Barthel H, Neuroimaging Committee of the European Association of Nuclear Medicine (EANM); Brain Imaging Council of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Role of (18)F-FDG-PET imaging in the diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15:1009–10.CrossRefPubMed
17.
go back to reference Graus F, Dalmau J. Role of (18)F-FDG-PET imaging in the diagnosis of autoimmune encephalitis - authors’ reply. Lancet Neurol. 2016;15:1010.CrossRefPubMed Graus F, Dalmau J. Role of (18)F-FDG-PET imaging in the diagnosis of autoimmune encephalitis - authors’ reply. Lancet Neurol. 2016;15:1010.CrossRefPubMed
18.
go back to reference Ances BM, Vitaliani R, Taylor RA, Liebeskind DS, Voloschin A, Houghton DJ, et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain. 2005;128:1764–77.CrossRefPubMedPubMedCentral Ances BM, Vitaliani R, Taylor RA, Liebeskind DS, Voloschin A, Houghton DJ, et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain. 2005;128:1764–77.CrossRefPubMedPubMedCentral
19.
go back to reference Trevino-Peinado C, Arbizu J, Irimia P, Riverol M, Martínez-Vila E. Monitoring the effect of immunotherapy in autoimmune limbic encephalitis using [18F]FDG PET. Clin Nucl Med. 2015;40:e441–3.CrossRefPubMed Trevino-Peinado C, Arbizu J, Irimia P, Riverol M, Martínez-Vila E. Monitoring the effect of immunotherapy in autoimmune limbic encephalitis using [18F]FDG PET. Clin Nucl Med. 2015;40:e441–3.CrossRefPubMed
20.
go back to reference Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain. 2010;133:1655–67.CrossRefPubMedPubMedCentral Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain. 2010;133:1655–67.CrossRefPubMedPubMedCentral
21.
go back to reference Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12:157–65.CrossRefPubMedPubMedCentral Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12:157–65.CrossRefPubMedPubMedCentral
22.
go back to reference Wegner F, Wilke F, Raab P, Ben Tayeb S, Boeck A, Haense C, et al. Anti-leucine rich glioma inactivated 1 protein and anti-N-methyl-D-aspartate receptor encephalitis show distinct patterns of brain glucose metabolism in 18F-fluoro-2-deoxy-D-glucose positron emission tomography. BMC Neurol. 2014;14:136.CrossRefPubMedPubMedCentral Wegner F, Wilke F, Raab P, Ben Tayeb S, Boeck A, Haense C, et al. Anti-leucine rich glioma inactivated 1 protein and anti-N-methyl-D-aspartate receptor encephalitis show distinct patterns of brain glucose metabolism in 18F-fluoro-2-deoxy-D-glucose positron emission tomography. BMC Neurol. 2014;14:136.CrossRefPubMedPubMedCentral
23.
go back to reference Chételat G, Desgranges B, De la Sayette V, Viadre F, Eustache F, Baron JC. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer’s disease? Neurology. 2003;60:1374–7.CrossRefPubMed Chételat G, Desgranges B, De la Sayette V, Viadre F, Eustache F, Baron JC. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer’s disease? Neurology. 2003;60:1374–7.CrossRefPubMed
24.
go back to reference van der Doef TF, Golla SS, Klein PJ, Oropeza-Seguias GM, Schuit RC, Metaxas A, et al. Quantification of the novel N-methyl-d-aspartate receptor ligand [11C]GMOM in man. J Cereb Blood Flow Metab. 2016;36:1111–21.CrossRefPubMed van der Doef TF, Golla SS, Klein PJ, Oropeza-Seguias GM, Schuit RC, Metaxas A, et al. Quantification of the novel N-methyl-d-aspartate receptor ligand [11C]GMOM in man. J Cereb Blood Flow Metab. 2016;36:1111–21.CrossRefPubMed
25.
go back to reference Bailey DL, Pichler BJ, Gückel B, Barthel H, Beer AJ, Botnar R, et al. Combined PET/MRI: from status quo to status go. Summary report of the Fifth International Workshop on PET/MR imaging. Mol Imaging Biol. 2016;18(5):637–50.CrossRefPubMedPubMedCentral Bailey DL, Pichler BJ, Gückel B, Barthel H, Beer AJ, Botnar R, et al. Combined PET/MRI: from status quo to status go. Summary report of the Fifth International Workshop on PET/MR imaging. Mol Imaging Biol. 2016;18(5):637–50.CrossRefPubMedPubMedCentral
26.
go back to reference Fayad H, Lamare F, Merlin T, Visvikis D. Motion correction using anatomical information in PET/CT and PET/MR hybrid imaging. Q J Nucl Med Mol Imaging. 2016;60(1):12–24.PubMed Fayad H, Lamare F, Merlin T, Visvikis D. Motion correction using anatomical information in PET/CT and PET/MR hybrid imaging. Q J Nucl Med Mol Imaging. 2016;60(1):12–24.PubMed
27.
go back to reference Chen KT, Izquierdo-Garcia D, Poynton CB, Chonde DB, Catana C. On the accuracy and reproducibility of a novel probabilistic atlas-based generation for calculation of head attenuation maps on integrated PET/MR scanners. Eur J Nucl Med Mol Imaging. 2016. Chen KT, Izquierdo-Garcia D, Poynton CB, Chonde DB, Catana C. On the accuracy and reproducibility of a novel probabilistic atlas-based generation for calculation of head attenuation maps on integrated PET/MR scanners. Eur J Nucl Med Mol Imaging. 2016.
28.
go back to reference Magistretti PJ. Cellular bases of functional brain imaging: insights from neuron-glia metabolic coupling. Brain Res. 2000;886:108–12.CrossRefPubMed Magistretti PJ. Cellular bases of functional brain imaging: insights from neuron-glia metabolic coupling. Brain Res. 2000;886:108–12.CrossRefPubMed
29.
go back to reference Yakushev I, Hammers A, Fellgiebel A, Schmidtmann I, Scheurich A, Buchholz HG, et al. SPM-based count normalization provides excellent discrimination of mild Alzheimer’s disease and amnestic mild cognitive impairment from healthy aging. Neuroimage. 2009;44:43–50.CrossRefPubMed Yakushev I, Hammers A, Fellgiebel A, Schmidtmann I, Scheurich A, Buchholz HG, et al. SPM-based count normalization provides excellent discrimination of mild Alzheimer’s disease and amnestic mild cognitive impairment from healthy aging. Neuroimage. 2009;44:43–50.CrossRefPubMed
30.
go back to reference Guedj E, Bonini F, Gavaret M, Trébuchon A, Aubert S, Boucekine M, et al. 18FDG-PET in different subtypes of temporal lobe epilepsy: SEEG validation and predictive value. Epilepsia. 2015;56:414–21.CrossRefPubMed Guedj E, Bonini F, Gavaret M, Trébuchon A, Aubert S, Boucekine M, et al. 18FDG-PET in different subtypes of temporal lobe epilepsy: SEEG validation and predictive value. Epilepsia. 2015;56:414–21.CrossRefPubMed
31.
go back to reference Antoine JC. Autoimmune encephalitis: paving the way for early diagnosis. Lancet Neurol. 2016;15:349–50.CrossRefPubMed Antoine JC. Autoimmune encephalitis: paving the way for early diagnosis. Lancet Neurol. 2016;15:349–50.CrossRefPubMed
Metadata
Title
The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis
Authors
Silvia Morbelli
Javier Arbizu
Jan Booij
Ming-Kai Chen
Gael Chetelat
Donna J. Cross
Mehdi Djekidel
Alexander Drzezga
Ozgul Ekmekcioglu
Valentina Garibotto
Swen Hesse
Kazunari Ishii
Lida Jafari Saraf
Adriaan A. Lammertsma
Ian Law
Dana Mathews
Satoshi Minoshima
Karina Mosci
Marco Pagani
Sabina Pappata
Daniel Hillel Silverman
Alberto Signore
Elsmarieke Van De Giessen
Victor Villemagne
Henryk Barthel
on behalf of the European Association of Nuclear Medicine (EANM) and of the Society of Nuclear Medicine and Molecular Imaging (SNMMI)
Publication date
01-03-2017
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2017
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3589-9

Other articles of this Issue 3/2017

European Journal of Nuclear Medicine and Molecular Imaging 3/2017 Go to the issue